Core Insights - Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to lead the U.S. launch and commercialization of NXC-201 for relapsed/refractory AL Amyloidosis, a rare blood disease with no current FDA-approved therapies [1][2] Company Overview - Immix Biopharma, Inc. is recognized as the global leader in relapsed/refractory AL Amyloidosis [6] - The company is focused on developing NXC-201, a CAR-T cell therapy designed to target and eliminate toxic light chains produced in AL Amyloidosis [5][7] Product Details - NXC-201 is a sterically-optimized BCMA-targeted CAR-T cell therapy that has received both Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation (ODD) from the FDA [5][7] - The therapy aims to address a significant unmet medical need in relapsed/refractory AL Amyloidosis, which is characterized by organ failure and high mortality rates [2][3] Market Insights - The AL Amyloidosis patient population in the U.S. is projected to grow at a rate of 12% annually, reaching approximately 37,270 patients by 2025 [3] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025 [4]

Clinical Development - Immix Biopharma's lead candidate NXC-201 is currently in clinical trials for relapsed/refractory AL Amyloidosis, with an overall response rate of 100% (10/10) and a complete response rate of 70% (7/10) reported in December 2023 [119]. - Immix Biopharma has treated 10 patients in the U.S. and 16 patients in ex-U.S. clinical trials for NXC-201 as of October 2025 [117]. - The FDA granted Orphan Drug Designation (ODD) to NXC-201 for AL Amyloidosis in September 2023, providing 7 years of exclusivity upon first approval for the disease [118]. - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to NXC-201 in February 2025, potentially streamlining the path to FDA approval [123]. - The Company expanded the number of clinical trial sites for NEXICART-2 to 18 in July 2025, enhancing its registrational design [125]. Financial Performance - The Company has incurred recurring losses primarily due to research and development activities, with significant expenses expected to continue as product candidates advance through clinical trials [128]. - General and administrative expenses increased to $3,078,378 for the three months ended September 30, 2025, up from $2,949,403 in the same period of 2024 [136]. - Research and development expenses rose to $4,584,131 for the three months ended September 30, 2025, compared to $4,445,528 in the prior year, driven by ongoing clinical trials [138][146]. - Net loss for the three months ended September 30, 2025, was $7,585,692, an increase from $7,149,395 in the same period of 2024 [141]. - The Company expects to require additional capital to fund operations beyond the next twelve months due to increasing expenses related to clinical programs and commercialization efforts [150][156]. Market Opportunity - The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is growing at a rate of 12% per year, estimated to reach 37,270 patients by 2025, with a current market size for amyloidosis therapies estimated at $3.6 billion, expected to reach $6 billion by 2027 [115]. - Immix Biopharma's other programs target a combined annual market size of $25 billion for serious immune-mediated diseases [127]. Funding and Grants - The Company received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) in July 2024 to support the clinical development of NXC-201 [121]. - The Company was awarded an $8 million grant from CIRM for the clinical development of NXC-201, with $4.6 million received in reimbursements as of November 2025 [132][153]. - The Company entered into a June 2025 ATM Agreement to sell up to $50 million in common stock, generating net proceeds of $2,573,375 from the sale of 1,087,381 shares during the nine months ended September 30, 2025 [133][154]. - In September 2025, the Company completed a private placement, selling 3,915,604 shares and warrants for gross proceeds of approximately $9.3 million [134][155]. Cash Flow and Assets - As of September 30, 2025, the Company had total assets of approximately $20.1 million and cash and cash equivalents of approximately $15.9 million [156]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $12,900,697, compared to $13,118,904 for the same period in 2024, reflecting a net loss of $18,750,783 in 2025 versus $16,886,309 in 2024 [162]. - Net cash used in investing activities was $567,799 for the nine months ended September 30, 2025, down from $670,529 in 2024, with both periods consisting solely of purchases of property and equipment [163]. - Net cash provided by financing activities was $11,718,263 for the nine months ended September 30, 2025, compared to $15,948,567 in 2024, primarily from proceeds of $11,878,678 from the sale of common shares in 2025 [164]. Interest Income - Interest income decreased to $84,539 for the three months ended September 30, 2025, down from $256,680 in the same period of 2024, due to lower cash balances [139][147]. - The Company anticipates significant commercialization expenses if marketing approval is obtained for its product candidates [150].

Core Insights - Immix Biopharma, Inc. focuses on NK cell-based immunotherapy, aiming to innovate within the biotech sector [1] Company Overview - The company has been under analysis for nearly two years, with a specific emphasis on its immunotherapy approach [1] - The analyst has a PhD in biochemistry and extensive experience in evaluating clinical trials and biotech firms, indicating a strong foundation for assessing the company's potential [1] Industry Context - The article highlights the importance of understanding the science behind biotech investments, suggesting that due diligence is crucial for investors in this sector [1]

Core Insights - Immix Biopharma, Inc. announced that interim results from its Phase 1/2 NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis will be presented at ASH 2025 [1][2] Industry Overview - AL Amyloidosis is a severe disease characterized by the immune system producing toxic light chains, leading to organ failure and death [3][7] - The U.S. patient population with relapsed/refractory AL Amyloidosis is projected to grow at a rate of 12% annually, reaching approximately 37,270 patients by 2025 [3] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025 [4] Company Overview - Immix Biopharma is recognized as the global leader in relapsed/refractory AL Amyloidosis, focusing on the development of NXC-201, a CAR-T cell therapy designed to target and eliminate toxic light chains [5][7] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [5][7] - The NEXICART-2 trial is a multi-site Phase 1/2 clinical study aimed at evaluating NXC-201, with an expected enrollment of 40 patients [6][7]

Core Insights - Immix Biopharma, Inc. announced that interim results from its Phase 1/2 NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis will be presented at ASH 2025 [2][3] Company Overview - Immix Biopharma is recognized as the global leader in relapsed/refractory AL Amyloidosis, a severe disease characterized by the immune system producing toxic light chains that lead to organ failure [4][8] - The company’s lead candidate, NXC-201, is a CAR-T cell therapy designed to target BCMA and has received both Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation from the FDA [6][8] Clinical Trial Information - The NEXICART-2 trial is an ongoing multi-site Phase 1/2 clinical study of NXC-201, which aims to enroll 40 patients and has a registrational design [7] - Interim results from this trial were previously presented at ASCO 2025, indicating ongoing progress in the clinical evaluation of NXC-201 [7] Market Insights - The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to grow at a rate of 12% annually, reaching approximately 37,270 patients by 2025 [4] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025, reflecting significant market potential for treatments [5]

Core Insights - Immix Biopharma, Inc. is a leader in relapsed/refractory AL Amyloidosis and will present at the Guggenheim 2nd Annual Healthcare Innovation Conference from November 10-12, 2025 [1] - The company will host one-on-one meetings with institutional investors during the conference [2] - ImmixBio's lead candidate is NXC-201, a CAR-T cell therapy, which has met its primary endpoint in an interim study [3] Company Overview - Immix Biopharma, Inc. (Nasdaq: IMMX) specializes in relapsed/refractory AL Amyloidosis and is developing NXC-201, a BCMA-targeted CAR-T cell therapy [3] - NXC-201 is currently being evaluated in the NEXICART-2 multi-center study in the U.S., with a registrational design [3] - The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [3]

Company Overview - Immix Biopharma, Inc. is a global leader in relapsed/refractory AL Amyloidosis, focusing on innovative therapies [4] - The lead candidate is NXC-201, a BCMA-targeted CAR-T cell therapy, currently evaluated in a multi-center study in the U.S. [4] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) from the FDA and EMA [4] Industry Insights - AL Amyloidosis is caused by abnormal plasma cells producing misfolded amyloid proteins, leading to organ failure and mortality [2] - The U.S. prevalence of relapsed/refractory AL Amyloidosis is estimated to grow at 12% annually, reaching approximately 37,270 patients by 2025 [2] - The Amyloidosis market was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025 [3] Clinical Developments - Immix Biopharma will present a NXC-201 abstract at the American Society of Hematology (ASH) 67 Annual Meeting in December 2025 [1] - The primary endpoint of the NEXICART-2 study for NXC-201 was met at interim results presented at ASCO 2025 [4]

Core Insights - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [3] - The company will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference from December 2-4, 2025 [1] - ImmixBio's lead candidate is NXC-201, a BCMA-targeted CAR-T cell therapy, which has met its primary endpoint in an interim study [3] Company Overview - Immix Biopharma, Inc. (Nasdaq: IMMX) is engaged in developing cell therapies specifically for AL Amyloidosis [3] - The lead product candidate, NXC-201, features a "digital filter" to minimize non-specific activation and is currently being evaluated in a multi-center study in the U.S. [3] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [3] Conference Details - The company will be available for one-on-one meetings during the Piper Sandler Healthcare Conference, and interested investors can contact their Piper Sandler representative for arrangements [2] - A replay of the presentation will be accessible on the Immix website under the Investors section [2]

Core Insights - Immix Biopharma is on track for the first FDA Biologics License Application (BLA) approved cell therapy for relapsed/refractory AL Amyloidosis, having surpassed the 50% enrollment milestone in the NEXICART-2 clinical trial [1][2] Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [5] - The lead candidate, NXC-201, is a sterically-optimized BCMA-targeted CAR-T cell therapy designed to filter out non-specific activation [4][5] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) from the FDA and EMA [4][5] Clinical Trial Details - NEXICART-2 (NCT06097832) is a multi-site Phase 1/2 clinical trial for NXC-201 in relapsed/refractory AL Amyloidosis, expected to enroll 40 patients [3] - Interim results from NEXICART-2 were presented at ASCO 2025, indicating positive progress towards BLA submission [2][5] Market Insights - The U.S. prevalence of relapsed/refractory AL Amyloidosis is projected to grow at 12% annually, reaching approximately 37,270 patients by 2025 [6] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to reach $6 billion by 2025 [7]

Core Insights - Immix Biopharma, Inc. has appointed Nancy T. Chang to its Board of Directors, who is a notable biotechnology leader and former CEO of Tanox, Inc. [1][2] - Dr. Chang's leadership at Tanox led to the development of several FDA-approved drugs, generating over $5 billion in sales [2] - Immix Biopharma is focused on developing cell therapies for AL Amyloidosis and other serious diseases, with its lead candidate being NXC-201, a CAR-T cell therapy [3] Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IMMX [3] - The company is developing NXC-201, which is currently being evaluated in a U.S. multi-center study for relapsed/refractory AL Amyloidosis [3] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [3] Product Development - The NEXICART-2 study for NXC-201 has met its primary endpoint at interim results presented at ASCO 2025 [3] - The therapy features a "digital filter" designed to eliminate non-specific activation [3]